IPO Timeline
Broker Results (T-2)
2021-06-28
Some brokers release in afternoon
Grey Market (T-1)
2021-06-29
Afternoon
HKEX Allotment (T-1)
2021-06-29
Evening
Registrar Allotment (T-1)
2021-06-29
Evening
Listing Day (T)
2021-06-30
First day of trading
Company Overview
| Stock Name | 和黃醫藥（中國）有限公司 |
|---|---|
| Stock Code | 00013 |
| Company Full Name | 和黃醫藥（中國）有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事開發及商業化治療癌癥及免疫性疾病的藥物，亦在中國從事藥物營銷及分銷業務。 |
| Listing Date | 2021-06-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍紅磡都會道10號都會大廈18樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.hutch-med.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 40.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 60.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 521,300,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 60.3 |
|---|---|
| First Day Open | HK$ 51.4 |
| First Day Change | 50.07% |
| First Day Volume | 34711300.0 |
| First Day Turnover | 2184790000.0 |
Use of Proceeds
| Use of Proceeds | 1、約19.75億港元（或50%）將用于推進賽沃替尼、索凡替尼、 呋喹替尼、HMPL-689及HMPL-523的后期臨床計劃以進行注冊試驗及潛在提交NDA申請； 2、約3.95億港元（或10%）將用于支持進一步的概念驗證研究，并資助內部研究以持續擴大我們的癌癥及免疫疾病產品組合； 3、約7.90億港元（或20%）將用于進一步增強我們在商業化、臨床、監管及生產方面的綜合實力； 4、約5.93億港元（或15%）將為潛在的全球業務發展及策略收購機會提供資金，以配合我們的內部研發活動，并提升我們目前的候選藥物管線； 5、約1.97億港元（或5%）將用作營運資金、在全球及中國擴大內部能力以及一般企業用途的資金。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (5)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
香港上海汇丰银行有限公司
Joint Bookrunners (10)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
香港上海汇丰银行有限公司
麦格理资本股份有限公司 CE AAC534
德意志银行香港分行
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
招商证券（香港）有限公司 CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | CA Fern Parent | 1,637,984,750 HKD | — | 39.28% | — | 6 months | 2021-12-30 |
| 2 | General Atlantic Singapore HCM Pte. Ltd. | 233,983,500 HKD | — | 5.61% | — | 6 months | 2021-12-30 |
| 3 | HBM Healthcare Investments (Cayman) Ltd. | 155,989,000 HKD | — | 3.74% | — | 6 months | 2021-12-30 |
| 4 | 加拿大退休金计划投资委员会 | 389,992,550 HKD | — | 9.35% | — | 6 months | 2021-12-30 |
| 5 | 中金启融(厦门)股权投资基金合伙企业(有限合伙) | 116,991,750 HKD | — | 2.81% | — | 6 months | 2021-12-30 |
Directors & Management
| Chairman | Dan Eldar |
|---|---|
| Company Secretary | 施熙德 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 長江和記實業有限公司(38.47%) |
|---|
IPO Timeline
